Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Global Pipeline Insight Report 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 6, 2019--
The “Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
Descriptive coverage of pipeline development activities
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products
The report assesses the active Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the report
Reasons to Buy
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cd671z
View source version on businesswire.com:https://www.businesswire.com/news/home/20191106005543/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 11/06/2019 08:26 AM/DISC: 11/06/2019 08:26 AM